Novo Holdings
Jeroen Bakker is a Partner at Novo Holdings where he’s driving investments on the intersection of human and planetary health and quantum technology. He has a decade of biotech investment experience, led and participated in several significant Seed and Series A investments and held board positions. He worked previously at M Ventures, the corporate VC group of Merck KGaA, and Syntaxin Ltd, an Oxford-based biotech which was acquired by Ipsen. He completed his PhD in Immunology at the Academic Medical Center Amsterdam.